NEPHROS NEPH 深 沪
交易中 09-20 14:50:12 美东时间
1.72
-0.085
-4.71%
华盛通- 最 高1.78
- 今 开1.78
- 成交量 1.20万股
- 最 低 1.67
- 昨 收 1.805
- 总市值 1803.40万
- 52周最高 4.0434
- 市盈率 静 --
- 换手率 0.11%
- 52周最低 1.40
- 委 比 6.10%
- 总股本 1048.49万
- 历史最高 11.666
- 量 比 4.48
- 振 幅 6.09%
- 历史最低 0.905
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nephros Shares 2024 Corporate Outlook and Plans
Nephros (NEPH) has shared an update. Nephros, Inc. has unveiled its updated 202...
08-27 04:29
Nephros GAAP EPS of -$0.03, revenue of $3.3M
Nephros press release (NASDAQ:NEPH): Q2 GAAP EPS of -$0.03. Revenue of $3.3M. More on Nephros Seeking Alpha’s Quant Rating on Nephros Historical earnings data for Nephros Financial information for Nep...
08-09 20:20
Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers
Gainers: Doximity DOCS +18%. Nephros (NEPH) +12%. Autolus Therapeutics ADR AUTL +12%. Capricor Therapeutics (CAPR) +12%. Notable Labs (NTBL) +9%. Losers: Heart Test Laboratories (HSCS) -33%. Lucy Scie...
05-17 22:00
Nephros files $50M mixed securities shelf
Nephros (NASDAQ:NEPH) filed a prospectus related to the offer and sale of $50M mixed securities shelf. This prospectus is not an offer to sell. Filing More on Nephros Seeking Alpha’s Quant Rating on N...
05-11 04:27
Benchmark Upgrades Nephros to Speculative Buy, Announces $5 Price Target
Benchmark analyst Robert Wasserman upgrades Nephros (NASDAQ:NEPH) from Hold to Speculative Buy and announces $5 price target.
03-09 02:46
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
03-07 17:49
Earnings Outlook For Nephros
Nephros (NASDAQ:NEPH) is set to give its latest quarterly earnings report on Th...
03-07 02:02
Talphera Announces $26M Capital Commitment Through A Combination Of A Non-Dilutive Royalty Monetization And Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025$16 million of total equity committed with $6
01-18 21:35
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Gainers Volcon (NASDAQ:VLCN) stock increased by 61.0% to $0.16 during Tuesday...
2023-12-27 01:32
